Strengthening the Evidence for Policy on the RTS,S/AS01 Malaria Vaccine
Key facts
- Who runs it
- Kintampo Health Research Centre, Ghana
- Where
- Ghana, Kenya, and Malawi4 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 9,280 people, planned
- Started
- 18 Oct 2021
- Planned end
- 30 Apr 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- Case-control study of clinical outcomes
- Case-control study of mortality outcome
- Record updated
- 28 February 2025
Who can take part
- Age
- 6 months to 59 months
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Willingness to participate in study evidenced by written informed consent provided by an adult caregiver
- Resident in an RTS,S/AS01 implementation area within the catchment area of MVPE sentinel hospitals
- Eligible, based on date of birth and age, to have received RTSS/AS01
- Meets the case or control definitions above
Who cannot take part
- Caregiver not willing to provide consent
This trial is currently available in Ghana, Kenya, and Malawi.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The ongoing Malaria Vaccine Pilot Evaluation (MVPE) is being conducted in Ghana, Malawi and Kenya through community and sentinel hospital surveillance systems and a series of household surveys (to measure vaccine coverage). The Malaria Vaccine Pilot Evaluation-Case Control (MVPE-CC) registered here as observational study is embedded within MVPE comprising case-control studies of clinical and mortality outcomes. Each case will require four controls, and caregiver informed consent will be required prior to study activities.
Read full original descriptionShow less
These observational case control studies will measure as complementary information to what is being collected through MVPE:
1. Safety among children who received the malaria vaccine, with focus on cerebral malaria, meningitis and severe malaria 2. The impact of the malaria vaccine on all-cause mortality for boys and girls, AND 3. Promote use of case-control approaches by Expanded Programmes on Immunization (EPI) and malaria control programmes.
The 2 groups in the trial
- Case-control study of clinical outcomes
These are children who live in RTS,S implementation areas aged less than 5 years and who were eligible to have received RTS,S based on their date or birth and age, will be eligible to be recruited into the study. Cases will be recruited in sentinel hospitals of the ongoing malaria Vaccine Pilot Evaluation (MVPE). Control for a case will be a child who lives outside a 100-metre radius from the case, matched on date of birth (+/- 1 month of date of birth of the case)
- Case-control study of mortality outcome
These will be children who died of any cause excluding accidents or trauma, who are eligible to have received the RTS,S vaccine based on their date of birth and age. Cases will be recruited from the community-based mortality surveillance of MVPE. Control for a mortality case will be a live child who lives outside a 100 metre radius from the case with date of birth +/- 1 month of the date of birth of the case who are eligible to have received the RTS,S vaccine.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Strengthening the Evidence for Policy on the RTS,S/AS01 Malaria Vaccine: Assessment of Safety and Effectiveness Using Case-control Studies Embedded in the Malaria Vaccine Pilot Evaluation
- Record updated
- 28 February 2025